An experimental skin cancer vaccine developed by pharmaceutical companies Moderna and Merck shows promising results after a five-year follow-up in clinical trials. The findings point to strong, lasting anti-tumour effects, and survival benefits for patients with advanced melanoma. The therapy, currently in phase 2 of clinical trial, combines Moderna’s custom mRNA technology, intismeran autogene, with Merck’s immunotherapy medicine Keytruda. Together, the treatments reduced the risk of cancer